Comparative Pharmacology
Head-to-head clinical analysis: ANGIO CONRAY versus GADOBUTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIO CONRAY versus GADOBUTROL.
ANGIO-CONRAY vs GADOBUTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angio-Conray (iothalamate meglumine) is a radiopaque contrast agent that attenuates X-rays, providing vascular opacification for angiographic procedures.
Gadobutrol is a gadolinium-based contrast agent (GBCA) that shortens T1 relaxation time in magnetic resonance imaging (MRI), enhancing signal intensity in tissues where it distributes. It is a paramagnetic agent that increases the relaxation rate of water protons in the vicinity of the gadolinium ion.
Intravenous: 0.5-1 mL/kg (maximum 100 mL) of a 60% solution for computed tomography; intra-arterial: varies by procedure, typically 5-80 mL of 60% or 76% solution.
0.1 mmol/kg (0.1 mL/kg) intravenous bolus; maximum dose 0.1 mmol/kg per contrast study. Repeat dosing up to 0.2 mmol/kg total during a single session may be considered on clinical judgment.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours; prolonged in renal impairment.
Terminal elimination half-life: 1.24-2.23 hours (healthy); may be prolonged in renal impairment (up to 9.6 hours in severe impairment).
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Primarily renal (90-95% unchanged within 24 hours); less than 0.3% fecal.
Category C
Category A/B
Contrast Agent
Contrast Agent